Dose intensity and the toxicity and efficacy of allogeneic hematopoietic cell transplantation

This publication has 20 references indexed in Scilit:

• Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors
  Blood, 2004
• Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities
  Blood, 2004
• Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation
  Blood, 2004
• Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients
  Blood, 2004
• Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma
  Blood, 2003
• Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation
  Blood, 2003
• Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning
  Blood, 2003
• Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation
  Blood, 2003
• Melphalan and purine analog–containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation
  Blood, 2001
• Antileukemic Effect of Graft-versus-Host Disease in Human Recipients of Allogeneic-Marrow Grafts
  New England Journal of Medicine, 1979